Scholarlink

<p>The article offers a review of the literature describing the embeddedness of financialisation in the innovation practices of pharmaceutical companies and its impact (Whitacre, 2024), through the prism of the accessibility of medicines. The argument is that financialisation is leading to a change in the business model of the pharmaceutical industry, marked by the transition from a broken ‘novo drug model’ to the gradual affirmation of a drug repositioning model, enabling more efficient management of the product life cycle. In doing so, and in order to maximise shareholder value, the pharmaceutical industry is abandoning the blockbuster model in favour of the nichebuster model. The latter favours the repositioning of drugs, intended for restricted patient populations, marketed at very high prices and generating substantial profits. This model thus accentuates the inaccessibility of drugs, which in a few decades has become a major global issue.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

What financialisation is doing to access to healthcare: price and value of medicines in financial capitalism

  • 期刊论文

  • 发表日期：

    2025年7月1日

查看全文
  • Samira Guennif

摘要

The article offers a review of the literature describing the embeddedness of financialisation in the innovation practices of pharmaceutical companies and its impact (Whitacre, 2024), through the prism of the accessibility of medicines. The argument is that financialisation is leading to a change in the business model of the pharmaceutical industry, marked by the transition from a broken ‘novo drug model’ to the gradual affirmation of a drug repositioning model, enabling more efficient management of the product life cycle. In doing so, and in order to maximise shareholder value, the pharmaceutical industry is abandoning the blockbuster model in favour of the nichebuster model. The latter favours the repositioning of drugs, intended for restricted patient populations, marketed at very high prices and generating substantial profits. This model thus accentuates the inaccessibility of drugs, which in a few decades has become a major global issue.